Adjunctive treatment of chronic idiopathic urticaria and angioedema with sulfasalazine

Results 20 patients were treated with Sulfasalazine as adjunctive therapy and 1 patient was lost to follow up. The patient’s ages ranged between 27-75 years with a mean of 48 years and 10 (50%) were female. IgE receptor antibody status was determined in 12 patients and 6 patients were positive. Out of the 19 patients who are still being followed, 10(52.6%) failed to respond to the Sulfasalazine, and 9 (47.4%) responded to Sulfasalazine with 2 partial responders and 7 complete responders. Side effects noted included: increased liver function tests, leucopenia, dyspepsia, flatulence nausea, pyrosis and a rash.